Disease Modifying Treatments and Symptomatic Drugs for Cognitive Impairment in Multiple Sclerosis: Where Do We Stand?

Multiple Sclerosis and Demyelinating Disorders - United Kingdom
doi 10.1186/s40893-017-0025-3
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

Targeting Angiogenesis in Cancer Treatments: Where Do We Stand?

Journal of Pharmacy and Pharmaceutical Sciences
MedicinePharmacologyPharmaceutical Science
2016English

Disease-Modifying Drugs for Relapsing-Remitting Multiple Sclerosis and Future Directions for Multiple Sclerosis Therapeutics

Archives of Neurology
1999English

Blockchain in Academia: Where Do We Stand and Where Do We Go?

2020English

Cognitive Impairment in Multiple Sclerosis

Current Neurology and Neuroscience Reports
NeuroscienceNeurology
2012English

High Energy Neutrino Astronomy: Where Do We Stand, Where Do We Go?

Physics of Particles and Nuclei
High Energy PhysicsNuclear
2018English

Schistosomiasis Vaccines: Where Do We Stand?

Parasites and Vectors
ParasitologyInfectious Diseases
2016English

Where Do We Stand After Coty?

Competition Law Journal
2018English

When and How Disease-Modifying Drugs for Multiple Sclerosis Should Be Changed in Daily Practice

Clinical and Experimental Neuroimmunology
NeuroscienceNeurologyImmunologyMicrobiology
2017English

Quantum Computers: Where Do We Stand?

Europhysics News
AstronomyPhysics
2005English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy